The team of scientists – including first author Jose Moreno, M.D., clinical associate professor of urology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and the Kimmel Cancer Center at Jefferson – looked at circulating tumor cells (CTCs) in 240 men with metastatic prostate cancer that failed hormone-depletion therapy. They compared levels prior to chemotherapy and after two to five weeks of treatment. They found that those men with more than five tumor cells per blood sample had a worse prognosis than those who had fewer cells. One half of the patients with more than five CTCs lived at least 10 months, whereas half of the men with fewer tumor cells lived substantially longer – 21 months.
Dr. Moreno presents the trial’s findings June 4, 2007 at the annual meeting of the American Society of Clinical Oncology in Chicago.
The results of the 65-site trial also showed that those patients who underwent chemotherapy and whose CTC number went down fared better and had a more favorable prognosis. That is, the level of response to chemotherapy was reflected in the CTC level, notes Dr. Moreno. The numbers held up even after up to 20 weeks of treatment. “If chemotherapy doesn’t reduce the CTC level, it’s information that enables the physician to change the drug regimen or perhaps stop treatment,” he says.
Dr. Moreno notes that the prostate specific antigen has been a powerful biomarker for cancer presence and a useful way to gauge treatment effectiveness for years, though it has some flaws. He thinks that the group’s findings show that CTCs can be a stronger marker.
“The other exciting aspect is in looking at men with earlier stage prostate cancer,” he says. “One in four men may have circulating tumor cells at an early stage of prostate cancer. If we can identify those patients, perhaps we can observe and not treat with radical surgery because their cancer is more dormant.”
Huntington Valley, Pa.-based Immunicon Corporation’s technology enabled researchers to visualize circulating tumor cells by using immunomagnetic beams that bind to the cell surface. It’s been Food and Drug Administration-approved for clinical use in breast cancer.
Immunicon currently is working with several pharmaceutical companies in identifying targets on circulating tumor cells that are susceptible to various chemotherapy drugs, he explains. “Then doctors can select specific chemotherapy agents for specific patients,” Dr. Moreno says. “The first immediate application is personalized medicine in advanced metastatic prostate cancer.”
In addition, certain tests can be performed on CTCs, he notes. One future goal is to better characterize the tumor cells virulence.
Yet, one limitation is that “we didn’t find as many circulating cells as we thought we would.” In the study, circulating tumor cells weren’t found in 38 percent of the men. “That might mean a better prognosis, but in fact their prognosis still isn’t very good,” he points out. “There are some limitations in our ability to detect them.”
Steve Benowitz | EurekAlert!
Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University
Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University
Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.
Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
16.11.2018 | Health and Medicine
16.11.2018 | Life Sciences
16.11.2018 | Life Sciences